Identification of the optimal donor quality scoring system and measure of early renal function in kidney transplantation.
BACKGROUND
The early identification of kidney allografts at risk of later dysfunction has implications for clinical practice. Donor quality scoring systems (preoperative) and measures of early allograft function (first week postoperative) have previously shown practical utility. This study aimed to determine the optimal parameter(s) (preoperative and postoperative) with greatest predictive power for the development of subsequent allograft dysfunction.


METHODS
Consecutive deceased donor renal transplants (n=217) were studied. In each, the following measures were assessed: Preoperative donor quality scores: expanded criteria donor status; Deceased Donor Score (Nyberg et al., Am J Transplant 2003;3:715); Donor Risk Score (Schold et al., Am J Transplant 2005; 5(4 pt 1): 757); and delayed graft function (DGF) Nomogram (Irish et al., J Am Soc Nephrol 2003; 14: 2967). Postoperative early function measures: dialysis requirement and duration; extended DGF definition (Boom et al., Kidney Int 2000; 58: 859); creatinine at day 5 and day 7; creatinine reduction ratios at day 2 and day 7; and urine output posttransplantation. Primary outcome measures were creatinine at 12 months and the development of chronic kidney disease stage 4T.


RESULTS
Of donor scoring systems, Donor Risk Score was best associated with subsequent allograft function. Of early function measures: the extended definition of DGF, creatinine at day 5, and dialysis duration showed greatest predictive power in the patient population overall, those not requiring postoperative dialysis, and those requiring dialysis, respectively. No scores or early function measures were associated with change in creatinine between 6 and 12 months.


CONCLUSIONS
This study validates and identifies the optimal early predictive parameter available for kidney transplant recipients, with implications for refining early postoperative management and potential utility in organ allocation policy.
Moore
Jason
J
Renal Institute of Birmingham, University Hospital Birmingham, Birmingham, United Kingdom.
Ramakrishna
Satish
S
Tan
Kay
K
Cockwell
Paul
P
Eardley
Kevin
K
Little
Mark A
MA
Rylance
Paul
P
Shivakumar
Kunigal
K
Suresh
Vijayan
V
Tomlinson
Kerry
K
Ready
Andrew
A
Borrows
Richard
R
D000328:Adult; D002102:Cadaver; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007668:Kidney / Q000502:physiology*; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D018579:Patient Selection; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D014019:Tissue Donors / Q000706:statistics & numerical data*; D014184:Transplantation, Homologous; D055815:Young Adult
D007166:Immunosuppressive Agents